



**QUEEN'S
UNIVERSITY
BELFAST**

Kunitzins: Prototypes of a new class of protease inhibitor from the skin secretions of European and Asian frogs

Chen, X., Wang, H., Chen, Y., Wang, L., Zhou, M., Chen, T., & Shaw, C. (2016). Kunitzins: Prototypes of a new class of protease inhibitor from the skin secretions of European and Asian frogs. *Biochemical and Biophysical Research Communications*, 477(2), 302-9. <https://doi.org/10.1016/j.bbrc.2016.06.062>

Published in:

Biochemical and Biophysical Research Communications

Document Version:

Peer reviewed version

Queen's University Belfast - Research Portal:

[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

© 2016 Elsevier Inc. All rights reserved.

This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

© Elsevier 2016

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

**Kunitzins: prototypes of a new class of protease inhibitor from the skin secretions of
European and Asian frogs**

Xiaole Chen^{1,*}, He Wang^{2,*}, Yue Shen³, Lei Wang³, Mei Zhou³, Tianbao Chen³, Chris Shaw³

1. School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China
2. School of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, 350001, Fujian, China
3. MedicineNatural peptide discovery group, School of Pharmacy, Queen's University, Belfast BT9 7BL, Northern Ireland, UK

* Corresponding author.

E-mail address: leochen5139@fjmu.edu.cn (Xiaole Chen); hwang11@qub.ac.uk (He Wang)

Abstract

Amphibian skin secretions contain biologically-active compounds, such as anti-microbial peptides and trypsin inhibitors, which are used by biomedical researchers as a source of potential novel drug leads or pharmacological agents. Here, we report the application of a recently developed technique within our laboratory to “shotgun” clone the cDNAs encoding two novel but structurally-related peptides from the lyophilized skin secretions of one species of European frog, *Rana esculenta* and one species of Chinese frog, *Odorrana schmackeri*. Bioanalysis of the peptides established the structure of a 17-mer with an N-terminal Ala (A) residue and a C-terminal Cys (C) residue with a single disulphide bridge between Cys 12 and 17, which is a canonical Kunitz-type protease inhibitor motif (-CKAAFC-). Due to the presence of this structural attribute, these peptides were named kunitzin-RE (AAKIILNPKFRCKAAFC) and kunitzin-OS (AVNIPFKVHLRCKAAFC). Synthetic replicates of these two novel peptides were found to display a potent inhibitory activity against *Escherichia coli* but were ineffective at inhibiting the growth of *Staphylococcus aureus* and *Candida albicans* at concentrations up to 160µM and both showed little haemolytic activity at concentrations up to 120µM. Subsequently, kunitzin-RE and kunitzin-OS were found to be a potent inhibitor of trypsin with a K_i of 5.56 µM and 7.56µM that represent prototypes of a novel class of highly-attenuated amphibian skin protease inhibitor. Substitution of Lys-13, the predicted residue occupying the P1 position within the inhibitory loop, with Phe (F) resulted in decrease in trypsin inhibitor effectiveness and antimicrobial activity against *Escherichia coli*, but exhibits a potential inhibition activity against chymotrypsin.

Key words: Amphibian; Venom; inhibitor; Peptide; Cloning; Antimicrobial

Introduction

Frogs have survived successfully over millions of years without detectable changes in their morphology. Their first-line of defence against predators and pathogens appears to be reliant on the synthesis and secretion of a complex array of bioactive molecules from highly-specialised dermal granular or poison glands that also appear to represent a primitive innate immune system^[1-2]. As modern analytical and mass spectrometric technologies develop, more novel peptides are being identified in and isolated from these complex amphibian defensive skin secretions. Meanwhile many peptides, which have hitherto been considered to be unique in one species, have been found to be widely-distributed in many structurally-related forms across different species. Scientists are also interested in studying different bioactivities among the newly discovered compounds secreted from frogs. The majority of these compounds are related to the amphibian defence system, such as antimicrobial peptides, neurotoxins, antioxidants and protease inhibitors^[1-4].

Protease inhibitors (PIs), widely found in animals, microorganisms and plants, are known to play key roles in the aetiology and treatment of human pathologies such as cancer, inflammation and haemorrhage, based on their inhibiting the catalytic activity of proteolytic enzymes^[5]. In addition, PIs appear to be a class of drugs representing a vital source of lead compounds for the treating or preventing of infection by viruses or pathogens, including HIV and Hepatitis C, in accordance with their capability of inhibiting the extracellular proteases which are believed to be widely produced by many pathogens (Christeller 2005). Thus PIs are useful tools to study and ultimately to better understand the functional principles of protein actives leading to the design of highly-specific drugs to control pathologic processes (Dockray et al 1975, Sampaio et al 1996, Goraya et al 1998).

Protease inhibitors are widely-distributed in amphibian skin secretions. Kunitz inhibitors have been found in the skin secretions of bombinid toads and ranid frogs, Kazal inhibitors in

phyllomedusine frogs and Bowman-Birk inhibitors in ranid frogs. Kunitz protease inhibitors usually contain four Cys residues that form two disulphide bridges and a single reactive centre as canonical structural features of the group [4,](Conlon et al 2009, Sampaio et al 1996, Goraya et al 1998). Furthermore, Kunitz-type inhibitors containing the rare signal peptide disulphide bridges have been isolated from frog skin secretions and this new type of trypsin inhibitor is apparently widely present in these secretions such that it can provide a wide spectrum of action templates for designing specific inhibitors for discrete protease targets (Lambert et al 2004).

In this study, we report the identification, structural characterisation, and cloning of skin-derived cDNAs that encode novel peptides with antimicrobial and potent trypsin inhibitory activities. Bioinformatic analysis indicated that both peptides contain a canonical Kunitz-type reactive centre and hence represent the smallest natural members of this established inhibitor family discovered to date. As a consequence of their structural and functional attributes, the peptides were named kunitzin-RE and kunitzin-OS. As the donor species (the European Edible frog, *Rana esculenta*, and the Chinese frog, *Odorrana schmackeri*), effectively represent the extremes of the range of Eurasian ranid frogs, it would not be unreasonable to suggest that kunitzins are of widespread occurrence in other species and this broad distribution may be reflective of an important if not fundamental role in the defence of the frogs. Meanwhile, the protease inhibitory potency of synthetic P1-substituted analogues (Phe¹³-kunitzins) and the catalytic loops were also synthesised and evaluated by comparing that of wild-type kunitzins for structure-activity relationship in this study.

Materials and methods

Preparation of skin secretion

Rana esculenta ($n=4$, 4–6cm snout to vent length) were obtained from a local herpetological supplier and *Odorrana schmackeri* ($n=3$, respectively) were captured during expeditions in the People's Republic of China. All frogs were adults and secretion harvesting was performed in the field after which frogs were released. Skin secretions were obtained from the dorsal skin using gentle transdermal electrical stimulation as previously described. The stimulated secretions were washed from the skin using deionised water and divided into either 0.2% v/v aqueous trifluoroacetic acid (for subsequent peptide characterisation), or into cell lysis/mRNA stabilisation buffer (Dyna) for subsequent cDNA library construction.

“Shotgun” cloning of skin secretion-derived cDNA

Five mg samples from each lyophilised skin secretion were separately dissolved in 1ml of cell lysis/mRNA protection buffer supplied by DynalBiotec, UK. Polyadenylated mRNA was isolated by the use of magnetic oligo-dT beads as described by the manufacturer (DynalBiotec, UK). The isolated mRNA was subjected to 3'-rapid amplification of cDNA ends (RACE) procedures to obtain full-length antimicrobial peptide precursor nucleic acid sequence data using a SMART-RACE kit (Clontech, UK) essentially as previously described. Briefly, the 3'-RACE reactions employed a nested universal primer (NUP), supplied with the kit, and a degenerate sense primer (5'-GTTCAACCATGAAGAAATCCCTGTTACT-3') that was designed to a highly conserved domain of the 5'-untranslated region of previously characterised antimicrobial/trypsin inhibitor peptide cDNAs from *Rana* species. The 3'-RACE reactions were purified and cloned using a pGEM-T vector system (Promega Corporation) and sequenced using an ABI 3730 automated sequencer.

Identification and structural analysis of novel precursor cDNA encoded peptides

Five mg samples from each lyophilised skin secretion were dissolved separately in 0.5ml of 0.05/99.95 (v/v) trifluoroacetic acid (TFA)/water and clarified of microparticulates by centrifugation. The supernatants were then separately subjected to reverse phase HPLC fractionation using a Cecil Adept Binary HPLC system (Adept Technology, Inc. USA) fitted with an analytical column (Phenomenex C-5; 0.46cm×25cm). This was eluted with a linear gradient formed from 0.05/99.5 (v/v) TFA/water to 0.05/19.95/80.0 (v/v/v) TFA/water/acetonitrile in 240min at a flow rate of 1ml/min. Fractions (1ml) were collected and the effluent absorbance was continuously monitored at $\lambda=214\text{nm}$. Samples (100 μl) were removed from each fraction in triplicate, lyophilised and stored at -20°C prior to bioactivity assays. The fractions that exhibited specified activity were subjected to MALDI-TOF MS analysis using a Perseptive Biosystems Voyager DE instrument (Framingham, MA, USA) in positive ion mode and α -cyano-4-hydroxycinnamic acid as matrix. Internal mass calibration of the instrument with peptide standards established the accuracy of mass determinations as $\pm 0.01\%$. Subsequently, each of the novel peptides were chemically synthesised using solid-phase Fmoc methodology on a PS3 automated peptide synthesiser (Protein Technologies Inc., AZ, USA). Products were purified and structures confirmed by LC/MS/MS.

Synthesis of kunitzins, the analogues (Phe¹³-kunitzins) and catalytic loops

Following unequivocal establishment of the primary structure of natural kunitzin-RE and kunitzin-OS, replicates were synthesised by solid-phase Fmoc chemistry using a PS3 automated peptide synthesiser (Protein Technologies, Tucson, AZ, USA). When the synthesis cycles were completed, the peptides were cleaved from the resins using 95/2.5/2.5 (v/v/v) TFA/TIPS/water for 6h, precipitated in ether over the next 24 h, washed exhaustively in six changes of ether and then allowed to completely dry over a further 24h. The peptides were then dissolved in a minimal quantity of 0.05/99.5, v/v, TFA/water, snap frozen in liquid

nitrogen and lyophilised. Degree of purity and authentication of structures of the synthetic peptides were determined using MALDI-TOF MS as previously described. The analogues (Phe¹³-kunitzins) and the catalytic loops of both wild-type and analogue peptides were also synthesised using the same method.

Antimicrobial assays

Antimicrobial activities of synthetic kunitzins and their analogues were assessed by determination of minimal inhibitory concentrations (MICs) using a standard Gram-positive bacterium *S. aureus*—NCTC 10788), a standard Gram-negative bacterium (*Escherichia coli*—NCTC 10418) and a standard pathogenic yeast (*Candida albicans* NCPF 1467). kunitzin-RE and kunitzin-OS were tested within the concentration range of 160–2.5µM and were initially dissolved as a stock solution of 200µM in sodium phosphate-buffered saline, pH 7.2, and subsequently diluted in Mueller–Hinton broth (MHB). Peptide concentrations in the range stated, were inoculated with microorganism cultures (10⁵ colony forming units (CFU)/ml), and placed into 96-well microtiter cell culture plates. Plates were incubated for 18 h at 37°C in a humidified atmosphere. Following this, the growth of bacteria/yeast was determined by means of measuring optical density (OD) at λ=550nm by an ELISA plate reader (BioliseBioTek EL808). Minimal inhibitory concentrations (MICs) were defined as the lowest concentration at which no growth was detectable.

Hemolysis assay

A 2% suspension of red blood cells was prepared from defibrinated horse blood (TCS Biosciences Ltd, UK). Kunitzin-RE and kunitzin-OS solutions of different concentrations were prepared as described in a previous section. Two hundred microlitres of the red blood cell suspension were incubated with a range of kunitzin-RE and kunitzin-OS concentrations similar to those employed for antimicrobial assays at 37°C for 2h. Lysis of red cells was assessed by measurement of optical density at λ=550nm using an ELISA plate reader

(BioliseBioTek EL808). Negative controls employed consisted of a 2% red cell suspension and sodium phosphate-buffered saline in equal volume and positive controls consisted of a 2% red cell suspension and an equal volume of sodium phosphate-buffered saline containing 2% of the non-ionic detergent, Triton X-100 (Sigma–Aldrich). The percent haemolysis was calculated using the following equation: %haemolysis= $(A-A_0) / (AX-A_0) \times 100$ where ‘A’ is absorbance at 550nm of controls employed consisted of a 2% red cell suspension in phosphate-buffered saline and ‘AX’ is absorbance at 550nm with 2% Triton X-100.

Trypsin inhibition assay.

Trypsin (10µl of a 0.1µM stock solution in 1mMHCl) was added to the wells of a microtitre plate containing substrate (Phe-Pro-Arg-NHMec, obtained from Sigma/Aldrich, Poole, Dorset, UK) (50µM) and either reconstituted chromatographic fraction (33%), in the first instance or, subsequently, synthetic peptide replicates (10–1000µM) in 10mM phosphate buffer, pH 7.4, containing 2.7mMKCl and 137mMNaCl (final volume 210µl). Each determination was carried out in triplicate. The rate of hydrolysis of substrate was monitored continuously at 37°C, by measuring the rate of increase of fluorescence due to production of 7-amino-4-methylcoumarin (NH₂Mec) at 460nm (excitation 360nm) in a FluoStar OPTIMA plate reader (BMG LABTECH, Germany)

Chymotrypsin inhibition assay.

Inhibitory activity assays on synthetic peptide replicates and their various P1-site-substituted variants against chymotrypsin, were performed exactly as detailed for the trypsin inhibition assay, except that the target protease was chymotrypsin and the fluorogenic substrate utilised was Succinyl-Ala-Ala-Pro-Phe-NHMec (obtained from Bachem, UK).

Trypsin cleavage of inhibitor peptides

1mg of trypsin (Sigma) and 1mg each of synthetic novel inhibitor peptides were separately incubated in 1 ml of sodium phosphate buffer, pH 7.2, at room temperature (25°C)

for 2h. Samples (20µl) were removed at 10 min intervals into 100µl of 0.05% (v/v) trifluoroacetic acid/water to terminate reactions. One microlitre of each was placed in separate wells of a MALDI-TOF sample plate, mixed with 1µl of matrix solution (α -cyano-4-hydroxycinnamic acid in 50/50 (v/v) water/acetonitrile), air dried and subjected to analysis on a Perceptive Biosystems DE MALDI-TOF instrument.

Result

“Shotgun” cloning of novel peptide-encoding cDNAs

The full-length kunitzin-RE and kunitzin-OS biosynthetic precursor-encoding cDNAs were separately and repeatedly cloned from the *R. esculenta* and *O. schmackeri* skin secretion cDNA libraries and each encoded a single copy of respective putative mature peptides (Figure 1). The NCBI BLAST search found that the novel peptides from *R. esculenta* and *O. schmackeri* showed at least 88% sequence identity, respectively, with Ranaturerin-2Ra and 2R from *R. ridibunda* (Figure 2A). In terms of the novel peptide precursor protein architectures, the N-terminal 22 amino acid residues encode a putative signal peptide and the following 29 amino acids constitute the acidic amino acid residue-rich spacer peptide domain that contains two classical-Lys-Arg- (-K-R-) propeptide convertase cleavage sites, the latter of which immediately flanks the N-terminus of the putative mature peptides. Both mature peptide sequences consisted of a 17-mer with an N-terminal Ala (A) residue and a C-terminal Cys (C) residue with a single disulphide bridge between Cys 12 and 17. The nucleotide sequences of the precursor-encoding cDNA of kunitzin-RE and kunitzin-OS have been deposited in Genbank Nucleotide Sequence Database under the accession code CCG00970 and AMW87025.

Isolation and structural characterisation of kunitzin-RE and kunitzin-OS from reverse phase HPLC fractions of skin secretion

Following prediction of the molecular masses of kunitzin-RE and kunitzin-OS from the cloned precursors and compensation for post-translational modification (single disulphide bridge formation in the C-terminal loop = -2amu), each mature peptide was identified in skin secretion HPLC fractions from respective species (Figure 3 and Table 1). Synthetic replicates of both novel peptides were successfully synthesised and obtained with a high degree of purity in the first attempt by the methodology employed and the molecular masses of the purified products were confirmed to be identical to those of the natural peptides by use of MALDI-TOF mass spectrometry analysis. The primary structures of kunitzin-RE and kunitzin-OS were determined by MS/MS fragmentation sequencing (Figure 4) unambiguously.

Antimicrobial/haemolytic activities of synthetic kunitzin-RE, kunitzin-OS and their analogues

Both the natural novel peptides and their synthetic replicates possessed relatively potent growth inhibitory activity against the Gram-negative bacterium, *E. coli* (Table 2), with MICs of $30\text{ }\mu\text{M}$ and $20\text{ }\mu\text{M}$, respectively, but were ineffective against the Gram-positive bacterium, *S. aureus* and the pathogenic yeast, *C. albicans* at concentrations up to $160\text{ }\mu\text{M}$. Both peptides possessed little haemolytic activity at concentrations up to and including $120\text{ }\mu\text{M}$.

Trypsin inhibition and peptide cleavage

Wide-type peptides and their synthetic replicates, kunitzin-RE and kunitzin-OS were found to possess relatively potent inhibitory activity against trypsin with K_i values of $5.56\text{ }\mu\text{M}$ and $7.56\text{ }\mu\text{M}$, respectively. A synthetic replicate of the cyclic C-terminal six-residue loop (-CKAAFC-) possessed no apparent trypsin-inhibitory activity.

Synthetic peptides with the natural Lys-13 residue occupying the P1 position within the inhibitory loop were the most potent trypsin inhibitors with no chymotrypsin activity even when employed at a concentration of 1mM . However, when Lys-13 was replaced by Phe (F), trypsin inhibitory activity was completely abolished and a modest inhibitory activity towards

chymotrypsin was observed. The resultant ‘Morrison plots’ (Table 3) derived from these latter progress curves, yielded K_i values of 17.5 μ M and 67.98 μ M for chymotrypsin inhibition by both site-substituted analogues, respectively.

The synthetic replicates of both novel natural peptides were cleaved by trypsin. The data obtained from these experiments are summarised in Table 4 and demonstrate that the cleavage fragments are generated through cleavage of classical trypsin sensitive sites. On the basis of these data, we presume that both inhibitor peptides act in a substrate-like manner and that they may compete with the synthetic trypsin-substrate for the active site of the enzyme.

Discussion

Various types of compounds synthesised and/or stored in frog skin, including amines, alkaloids and peptides, form a fundamental part of their anti-predator defence systems. In response to stress, compression of the peptide-containing serous cells is initiated and these host-defence peptides, stored in the granular glands, are secreted by a holocrine-like mechanism onto the dorsal surface [2](Bode et al 1992, McPhee et al 2005, Otvos 2005). Serine protease inhibitors are one of the most studied groups of natural biomolecules as they play key roles in controlling blood coagulation and inflammation as well as a large number of other essential life processes. In Nature, protein-based protease inhibitors protect the host against a range of extrinsic proteases produced by invading microorganisms (Tamechika et al 1996) and these inhibitors can be generally classified according to the presence of a defined structural motif as Kunitz, Kazal or Bowman- Birk (Zasloff 1987). The Bowman-Birk-like trypsin inhibitor from the skinsecretion of *Huia versabilis* (HV-BBI), exhibits a potent inhibition against trypsin^[4]. The Kunitz-type trypsin inhibitor isolated from the skin secretion of *Dyscophusguineti*, a species which apparently does not produce classical antimicrobial peptides, is proposed to play a role as an anti-infective agent (Zasloff 2002).

In the present study, two novel peptides, each containing 17 amino acid residues, have been identified from two different species of frog representing two continents, Europe and Asia, and both contain six-residue C-terminal disulphide-bridged loops (-CKAAFC-), formed by two cysteine residues. This conserved six-residue loop is suggestive of an antimicrobial function for these novel peptides as the ranatuerin-2 family of frog skin antimicrobial peptides display a C-terminal cyclic hexapeptide domain rather than the more common heptapeptide of others (Otvos 2005, Zasloff 2002). However, while the ranatuerin-2 family of peptides first identified in the bullfrog, *Lithobates catesbeianus* (Pukala et al 2006), have a marked variation in their amino acid sequences and some members, for example, the potent broad-spectrum antimicrobial peptide ranatuerin-2CSa isolated from the Cascades frog, *Rana cascadae* (Pukala et al 2006), have been proposed as templates for antibacterial drug development, the two novel peptides discovered here display no structural similarity with ranatuerins and only limited antimicrobial activity against the Gram-negative bacterium, *E. coli*, are hence not members of this family. Thus the analogues previously identified in the skin secretion of *Rana ridibunda*, have been named erroneously.

Further biological investigations on the two novel peptides found both to be rather potent inhibitors of trypsin with K_i values of approximately 5.56 and 7.56 μM , for the *Rana esculenta* (RE) and *Odorrana schmackeri* (OS) peptides, respectively. Bioinformatic analysis of the primary structures of the two novel peptides established that they exhibited structural similarity to the “so-called” *Rana ridibunda* ranatuerins – a nomenclature that is erroneous as discussed previously, and to a series of trivially named antimicrobial peptides from several species of Chinese frogs, most notably from the ranid genus, *Amolops*, all of which are unpublished observations. These data however, imply that the peptides described in this study, are of widespread occurrence in the skins of a considerable number of species from a variety of ranid frog taxa of both European and especially of Asian origin. Such widespread

expression and conservation of peptide structure across taxa is often indicative of a fundamental biological role.

Bioinformatic analysis of the primary structure of the novel peptides indicated that the C-terminal disulphide-bridged loop exhibited a high degree of identity with the inhibitory loops of several Kunitz-type protease inhibitors from a variety of sources (Figure 2B), all of which possess either a Lys (K) or an Arg (R) residue in the P1 site. This residue confers specificity for trypsin and proteases that cleave with a trypsin-like cleavage site specificity following a basic amino acid residue. For this reason and for the potent trypsin inhibitory activity displayed by both peptides, we named these peptide kunitzins as prototypes of a novel class of protease inhibitor from amphibian skin secretions.

The P1 site is occupied by a Lys (K) residue in the conserved kunitzin motif, -CKAAFC, and synthetic analogues of both peptides incorporating a Phe (F) residue in this position (-CFAAFC-), displayed little inhibitory activity against trypsin even completely losing this ability, although they then exhibited a modest inhibitory activity against chymotrypsin. Thus, from the limited structure/activity data presented here, a Lys residue has apparently been selected by Nature to occupy this site within the six-residue loop and direct the inhibitory activity of the kunitzin towards a protease or proteases with trypsin-like cleavage specificity. Once the basic Lys residue in this P1 position is replaced by an aromatic amino acid residue (F), such analogues lose trypsin inhibitory activity and at the same time, their antimicrobial activity in addition. These data have also supplied evidence that the cyclic six-residue loop (-CKAAFC), has no inhibitory activity against trypsin in its own right and must require other features of the primary structure of the peptides to achieve this.

An observation of interest was that both kunitzins were catabolised by trypsin and identification of the catabolites of each peptide using MS showed that tryptic cleavages involved were classical. We presume that these fragments may play some roles in the other

biological processes or that they may serve to imply that kunitzins act as pseudo-substrates and that this represents their mode of inhibitory action. Of interest was the fact that the C-terminal loop structure was not identified until late in respective incubations which would imply that this highly-ordered structure was maintained in the reactive center of the trypsin until cleaved after the Lys residue. The incremental increase in molecular mass of 18 amu observed for this fragment in late incubation would be consistent with hydrolysis of the Lys-X bond but with retention of the catabolite as a loop structure.

The complex cocktail of compounds stored in the glandular glands of frogs consist of at least one broad-spectrum antibiotic peptide together with a number of other narrow-spectrum activity peptides which act against one or several kinds of bacteria. These narrow-spectrum antibacterial peptides can not only supply enhanced protection against a range of bacteria, but also have other roles in the defence system. An example of this are the caerins 2.1, isolated from *Litoria splendida*. These are narrow-spectrum antibiotic peptides against some Gram-negative organisms but also inhibit the production of nitric oxide by neuronal nitric oxide synthase (Otvos 2005).

There are a number of principles used to explain the membrane permeation or lytic mechanisms that lead to the death of microorganisms. The most important one is the fundamental structural principle known as amphipathic design. The peptides, containing clusters of hydrophobic and cationic amino acids, are able to adopt a shape to bind the membrane bilayer leading to cell lysis. These processes are thought to disturb the membrane or induce 'wormhole' formation so that the peptides can be transported into the inner leaflet and then produce defined pores, causing death of the target cell. Such kinds of peptides are usually linear and possess an α -helical secondary structure but most *Rana* frog peptides have instead modified C-terminal sequences with a single disulphide loop using a rigid anti-

parallel β -sheet as the framework (Otvos 2005, Qi et al 2005a, Qi et al 2005b, Song et al 2008).

As a type of Kunitz trypsin inhibitor, kunitzins also exhibit a narrow-spectrum antibacterial activity against the Gram-negative bacterium, *Escherichia coli*. These unusual peptides may be transported into the inner bacterial membrane to disrupt multiple cellular processes or additionally target a trypsin-like protease inside the Gram-negative bacteria resulting in their death. However the antibacterial mechanisms are still unclear and require further investigation.

Acknowledge

This work was supported by National Natural Science Foundation, China (Grant No. 81402842), Natural Science Foundation of Fujian Province, China (Grant No. 2015J05162), Natural Science Foundation of Fujian Province, China (Grant No. 2016J01374), Fujian Provincial outstanding talents for Education and Scientific research (Grant No. JK2014016) and The doctor startup foundation of Fujian Medical University (Grant No.2012bs002).

Conflict of Interest statement

The authors declare that they have no conflict of interest.

Ethical statement

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Data deposition footnotes

The nucleotide sequences of the kunitzin-RE and kunitzin-OS precursors have been deposited in the Genbank Nucleotide Sequence Database under the accession code CCG00970 and AMW87025.

References

- Christeller, J. T. (2005). REVIEW ARTICLE: Evolutionary mechanisms acting on proteinase inhibitor variability. *The FEBS Journal*, 272, 22, 5710-5722.
- Dockray, G. J., & Hopkins, C. R. (1975).Caerulein Secretion by Dermal Glands in *Xenopus laevis*. *The Journal of Cell Biology*, 64, 3, 724-733.
- Sampaio, C. A., Oliva, M. L., Sampaio, M. U., Batista, I. F., Bueno, N. R., Tanaka, A. S., Auerswald, E. A., Fritz, H. (1996).Plant serine proteinase inhibitors.Structure and biochemical applications on plasma kallikrein and related enzymes.*Immunopharmacology*, 32, 1-3.
- Goraya, J., Knoop, F., & Conlon, J. (1998).Ranatuerins: Antimicrobial Peptides Isolated from the Skin of the American Bullfrog, *Rana catesbeiana*. *Biochemical and Biophysical Research Communications*, 250, 3, 589.
- Lambert, E., Dassé, E., Haye, B., & Petitfrère, E. (2004).TIMPs as multifacial proteins.*Critical Reviews in Oncology*, 49, 3, 187-98.
- Lingaraju, M. H., & Gowda, L. R. (2008). A Kunitz trypsin inhibitor of *Entadas scandens* seeds: another member with single disulfide bridge. *Biochimica Et Biophysica Acta*, 1784, 5, 850-5.
- McPhee, J. B., & Hancock, R. E. (2005). Function and therapeutic potential of host defence peptides. *Journal of Peptide Science*, 11, 11, 677-87.
- Otvos, L. J. (2005). Antibacterial peptides and proteins with multiple cellular targets.*Journal of Peptide Science*, 11, 11, 697-706.
- Pukala, T. L., Bowie, J. H., Maselli, V. M., Musgrave, I. F., & Tyler, M. J. (2006). Host-defence peptides from the glandular secretions of amphibians: structure and activity. *Natural Product Reports*, 23, 3, 368-93.

- Qi, R. F., Song, Z. W., & Chi, C. W. (2005). Structural features and molecular evolution of Bowman-Birk protease inhibitors and their potential application. *Acta Biochimica Et Biophysica Sinica*, 37, 5, 283-92.
- QI, R.-F., SONG, Z.-W., & CHI, C.-W. (2005). Structural Features and Molecular Evolution of Bowman-Birk Protease Inhibitors and Their Potential Application. *Acta Biochimica Et Biophysica Sinica*, 37, 5, 283-292.
- Song, G., Zhou, M., Chen, W., Chen, T., Walker, B., & Shaw, C. (2008). HV-BBI--A novel amphibian skin Bowman-Birk-like trypsin inhibitor. *Biochemical and Biophysical Research Communications*, 372, 1, 191.
- Tamechika, I., Itakura, M., Saruta, Y., Furukawa, M., Kato, A., Tachibana, S., & Hirose, S. (1996). Accelerated evolution in inhibitor domains of porcine elafin family members. *The Journal of Biological Chemistry*, 271, 12, 7012-8.
- Zasloff, M. (1987). Magainins, a Class of Antimicrobial Peptides from *Xenopus* Skin: Isolation, Characterization of Two Active Forms, and Partial cDNA Sequence of a Precursor. *Proceedings of the National Academy of Sciences of the United States of America*, 84, 15, 5449-5453.
- Zasloff, M. (2002). Antimicrobial peptides of multicellular organisms. *Nature*, 415, 6870, 389-95.
- Zhang, R., Zhou, M., Wang, L., McGrath, S., Chen, T., Chen, X., & Shaw, C. (2010). Phylloseptin-1 (PSN-1) from *Phyllomedusa sauvagei* skin secretion: A novel broad-spectrum antimicrobial peptide with antibiofilm activity. *Molecular Immunology*, 47, 2030-2037.

Legends to Figures

Figure 1. Nucleotide and translated open-reading frame amino acid sequences of cloned cDNAs encoding the biosynthetic precursors of (A) kunitzin-RE and (B) kunitzin-OS. Putative signal peptides are double-underlined, mature peptides are single-underlined and the respective stop codons are indicated by asterisks.

Figure 2. (A) The primary structures of the novel kunitzin peptides from *R. esculenta* and *O. schmackeri* skin secretion compared with Ranatuerin-2Ra and 2R from *R. ridibunda*, respectively. Fully conserved residues are indicated with asterisks. Please note that bioinformatic analysis has indicated that the *R. ridibunda* ranatuerin peptides are NOT structurally-related to canonical ranatuerins. (B) Comparison of the reactive centre of kunitzins with those from other selected Kunitz-type protease inhibitors. BPTI=Bovine pancreatic trypsin inhibitor; APPI=Amyloid protein precursor inhibitor; AAPH=Amyloid precursor protein homologue; TFPI=Tissue factor pathway inhibitor; HA1=Hepatocyte growth factor activator inhibitor; PLI=Porcine leukocyte inhibitor; UPTI=Uterine plasmin/trypsin inhibitor; SPI=Silk proteinase inhibitor; AsKC=*Anemoniasulcata* kalichludine.

Figure 3. Region of reverse phase HPLC chromatograms of the skin secretions of *Rana esculenta* (A) and *Odorrana schmackeri* (B) with arrows indicating elution/ retention times kunitzin-RE and kunitzin-OS, respectively. The Y-axis indicates absorbance units at $\lambda=214\text{nm}$.

Figure 4. Predicted b- and y-ion MS/MS fragment ion series (singly- and doubly- charged) of kunitzin-RE (A) and kunitzin-OS (B). Observed ions are indicated in bold typeface.

Legends to Tables

Table 1 Molecular masses and primary structures of Kunitzin-RE and Kunitzin-OS identified in semi-preparative reverse phase HPLC fractions of *R. esculenta* and *O. schmackeri* skin secretion, respectively. The calculated (calc) and observed (obs) masses are monoisotopic. Mr (obs) values are deduced from the protonated molecules.

Table 2 Inhibitor constants for 'wide-type' kunitzin-RE and -OS and their respective P1 site-substituted variants against trypsin and chymotrypsin.

Table 3 Minimum inhibitory concentrations (μM) of synthetic replicates of kunitzin-OS and kunitzin-RE and their P1 site-substituted variants, against reference strains of microorganisms used in this study.

Table 4 Catabolites generated by incubation of Kunitzin-RE and Kunitzin-OS with trypsin. Computed molecular masses of kunitzin tryptic catabolites compared to those detected by MALDI-TOF MS.

(A)

(B)

[illegible]

Figure 2

(A)


Kunitzin-RE	AAKIILNPKFRCKAAFC
Ranatuerin-2Ra	AAKLLLNPkFRCKAAFC
	*** *****
Kunitzin-OS	AVNIPFKVHLRCKAAFC
Ranatuerin-2R	AVNIPFKVKFRCKAAFC
	***** *****

(B)

	N----	P ₄ P ₃ P ₂ P ₁ P ₁ '	P ₂ '	P ₃ '	P ₄ '	----	C
Kunitzin	---	F	R	C	<u>K</u>	<u>A</u>	A F C
SPI 1	---	G	P	C	<u>K</u>	<u>A</u>	A F Q---
BPTI	---	G	P	C	<u>K</u>	<u>A</u>	I M K---
TFPI Domain 1	---	G	P	C	<u>K</u>	<u>A</u>	I M K---
PLI	---	G	P	C	<u>K</u>	<u>A</u>	R M I---
APPI	---	G	P	C	<u>R</u>	<u>A</u>	M I I---
AAPH	---	G	P	C	<u>R</u>	<u>A</u>	V M P---
TFPI Domain 3	---	G	L	C	<u>R</u>	<u>A</u>	N E N---
HAI-2 Domain 1	---	G	R	C	<u>R</u>	<u>A</u>	S M P---
UPTI	---	G	P	C	<u>R</u>	<u>A</u>	H F I---
AsKC-1	---	G	R	C	<u>R</u>	<u>A</u>	S H P---

Figure 3

(A)



(B)




Figure 4**(A)**

#1	b(1+)	b(2+)	Seq.	y(1+)	y(2+)	#2
1	72.04440	36.52584	A			17
2	143.08152	72.04440	A	1823.01836	912.01282	16
3	271.17649	136.09188	K	1751.98124	876.49426	15
4	384.26056	192.63392	I	1623.88627	812.44677	14
5	497.34463	249.17595	I	1510.80220	755.90474	13
6	610.42870	305.71799	L	1397.71813	699.36270	12
7	724.47163	362.73945	N	1284.63406	642.82067	11
8	821.52440	411.26584	P	1170.59113	585.79920	10
9	949.61937	475.31332	K	1073.53836	537.27282	9
10	1096.68779	548.84753	F	945.44339	473.22533	8
11	1252.78891	626.89809	R	798.37497	399.69112	7
12	1355.79810	678.40269	C	642.27385	321.64056	6
13	1483.89307	742.45017	K	539.26466	270.13597	5
14	1554.93019	777.96873	A	411.16969	206.08848	4
15	1625.96731	813.48729	A	340.13257	170.56992	3
16	1773.03573	887.02150	F	269.09545	135.05136	2
17			C	122.02703	61.51715	1

(B)

#1	b(1+)	b(2+)	Seq.	y(1+)	y(2+)	#2
1	72.04440	36.52584	A			17
2	171.11282	86.06005	V	1845.99795	923.50261	16
3	285.15575	143.08151	N	1746.92953	873.96840	15
4	398.23982	199.62355	I	1632.88660	816.94694	14
5	495.29259	248.14993	P	1519.80253	760.40490	13
6	642.36101	321.68414	F	1422.74976	711.87852	12
7	770.45598	385.73163	K	1275.68134	638.34431	11
8	869.52440	435.26584	V	1147.58637	574.29682	10
9	1006.58331	503.79529	H	1048.51795	524.76261	9
10	1119.66738	560.33733	L	911.45904	456.23316	8
11	1275.76850	638.38789	R	798.37497	399.69112	7
12	1378.77769	689.89248	C	642.27385	321.64056	6
13	1506.87266	753.93997	K	539.26466	270.13597	5
14	1577.90978	789.45853	A	411.16969	206.08848	4
15	1648.94690	824.97709	A	340.13257	170.56992	3
16	1796.01532	898.51130	F	269.09545	135.05136	2
17			C	122.02703	61.51715	1

Table 1

Peptide	Fraction	Mr(obs)	Mr(calc)	Primary structure
Kunitzin-RE	104	1893.50	1894.39	AAKIILNPKFRCKAAFC
Kunitzin-OS	100	1916.65	1917.38	AVNIPFKVHLRCKAAFC

Table 2

Peptide	Ki (μM) (trypsin)	Ki (μM) (chymotrypsin)
AAKIILNPKFRCKAAFC	5.56	N.I.*
AAKIILNPKFRCFAAFC	48.37	17.5
AVNIPFKVHLRCKAAFC	7.56	329
AVNIPFKVHLRCFAAFC	N.I.*	67.98
VHLRCKAAFC	86.54	N.I.*
CKAAFC	N.I.*	N.I.*

*No inhibition was observed using peptide concentrations up to and including 1mM.
P1 position is highlighted.

Table 3

Peptide	<i>E.coli</i> (μM)	<i>S.aureus</i> (μM)	<i>Candida</i> (μM)
AAKIILNPKFRCKAAFC	30	NA*	NA*
AAKIILNPKFRCFAAFC	160	NA*	NA*
AVNIPFKVHLRCKAAFC	20	NA*	NA*
AVNIPFKVHLRCFAAFC	NA*	NA*	NA*
VHLRCKAAFC	NA*	NA*	NA*
CKAAFC	NA*	NA*	NA*

NA* = not active using peptide concentrations up to and including 200μM.

Table 4

Peptide	Sequence	Mr(calc)	Mr(obs)
Kunitzin-RE 1-17	AAKIILNPKFRCKAAFC	1894.39	1894.85
Kunitzin-RE 4-17	IILNPKFRCKAAFC	1624.06	1625.23
Kunitzin-RE 1-11	AAKIILNPKFR	1270.58	1271.22
Kunitzin-RE 1-9	IILNPKFR	1000.25	1000.67
Kunitzin-RE 4-11	AAKIILNPK	967.21	968.05
↓ site means the cleavage position AAK ↓ IILNPK ↓ FR ↓ CKAAFC			

Peptide	Sequence	Mr(calc)	Mr(obs)
Kunitzin-OS 1-17	AVNIPFKVHLRCKAAFC	1917.38	1916.87
Kunitzin-OS 1-11	AVNIPFKVHLR	1293.57	1293.15
Kunitzin-OS 1-7	AVNIPFK	787.95	786.72
↓ site means the cleavage position AVNIPFK ↓ VHLR ↓ CK ↓ AAFC			